Nitrogen Dioxide Toxicity Treatment & Management
- Author: Nader Kamangar, MD, FACP, FCCP, FCCM; Chief Editor: Ryland P Byrd, Jr, MD more...
If no initial symptoms are present, observe the patient for at least 12 hours for hypoxemia. Hospitalize the patient for 12-24 hours for observation or longer if gas exchange is compromised. Noncardiogenic pulmonary edema can take up to 48 hours to develop. Educate the patient on the possible symptoms and instruct the patient to return if the symptoms develop.
Administer oxygen to the patient for hypoxemia. Intubation and mechanical ventilation may be necessary if gas exchange is severely impaired. Treat secondary infection, if present.
Administer volume expanders cautiously. The patient may require invasive monitoring because excessive administration of volume expanders can cause hydrostatic pulmonary edema. Nitrogen dioxide (NO2) forms nitric oxide, causing vasodilation and an apparent volume depletion.
Transferring the patient to a tertiary care center for further diagnostic evaluation and ventilatory support may be necessary.
Prehospital and Emergency Department Care
Rescuers must remove the patient from the source of exposure without endangering themselves. Wearing a self-contained breathing apparatus (SCBA) may be indicated. The patient should then receive supplemental oxygen, and, if needed, airway management and ventilatory support.
The primary emergency department (ED) treatment of NO2 -induced respiratory illness is supportive therapy directed at correction of hypoxemia, ventilatory failure, and secondary infection. Endotracheal intubation and mechanical ventilation may be required, depending on the degree of respiratory distress and hypoxemia. High-dose corticosteroids are suggested in the treatment of pulmonary manifestations, but data on their prophylactic use after nitrogen dioxide (NO2) exposure is anecdotal.
Monitor continuous pulse oximetry. Pulse oximetry monitoring may be misleading in the presence of methemoglobinemia, however.
Patients who have been exposed to nitrogen dioxide (NO2) should be admitted for at least 24 hours if they have any of the following:
Altered mental status
A widened alveolar-arterial oxygen gradient
In patients who are critically ill, placement of a pulmonary artery catheter for monitoring of mixed venous oxygenation and pulmonary vascular resistance may assist in the management of oxygenation requirements, fluids, acute respiratory distress syndrome (ARDS), and physiologic variables.
Evidence of significant methemoglobinemia should prompt treatment with methylene blue (see Medication). Clinical improvement and resolution of hypoxemia and methemoglobinemia are helpful endpoints for discharge. Advise the patient to avoid exercise for 1-2 days after exposure.
In prolonged cases of toxicity with evidence of proliferative bronchiolitis obliterans, patients may be responsive to steroid therapy. Resolution of symptoms generally occurs slowly over a period of several months. There is little data to suggest that prophylactic steroids will prevent development of bronchiolitis obliterans. As mentioned above, constrictive bronchiolitis is not as responsive to steroid therapy.
Working environments should be evaluated for elevated nitrogen dioxide (NO2) levels and proper ventilation and protective gear, such as SCBA, should be used. American Conference of Governmental Industrial Hygienists threshold limit values (ACGIH-TLV) for NO2 are as follows:
Time weighted average (TWA): 3 ppm
Short-term exposure limit (STEL): 5 ppm
National Institute of Occupational Safety and Health (NIOSH) values are as follows:
Recommended exposure limit (REL): 1 ppm
STEL (immediately dangerous to life or health): 20 ppm
National Fire Protection Association (NFPA) hazard ratings are as follows:
Health (Blue) - 3
Flammability (Red) - 0
Reactivity (Yellow) - 0
Other workplace safety measures are as follows:
Labels required: Poison gas, oxidizer, corrosive
Respiratory equipment recommendations: Positive-pressure SCBA (according to North American Emergency Response Guide [NAERG] 124)
Protective clothing: Chemically protective clothing, as recommended by the manufacturer (according to NAERG 124)
Exposure to air pollution and nitrogen dioxide in particular is increasingly recognized as a significant factor in the development of asthma, COPD and pulmonary disease. Some studies suggest the potential for antibiotics or anti-oxidants such as vitamin C or vitamin E to prevent or mitigate the progression of disease.[24, 25] This remains an area in need of ongoing research.
Consult a pulmonary medicine or critical care specialist if the patient requires endotracheal intubation or hemodynamic monitoring. Consult with a regional poison control center or a local medical toxicologist (certified through the American Board of Medical Toxicology and/or the American Board of Emergency Medicine) to obtain additional information and patient care recommendations.
When a patient who has been placed on corticosteroid therapy acutely is discharged, prescribe corticosteroid taper for at least 8 weeks. Most authors agree that patients with bronchiolitis obliterans should be maintained on corticosteroids until their symptoms have resolved. A longer duration of therapy (ie, 6-12 months) may be indicated if symptoms of bronchiolitis obliterans persist or recur after initial steroid taper.
Inhaled sympathomimetics (eg, albuterol), anticholinergics (eg, ipratropium bromide), and steroids (eg, fluticasone propionate) may also be indicated if the patient develops symptoms of reactive airway disease. A typical asthma disease management plan can be used for these patients.
Conduct follow-up examinations at 1 week, 1 month, and 3 months after exposure, with serial pulmonary function testing and radiographs.
Multiple studies have shown an increased association between bacterial pneumonia, increased mortality, and inhalational exposures.[26, 27, 28] At this time, however, the use of prophylactic antibiotics has not shown any long-term benefits in randomized controlled trials. Given the propensity for development of antibiotic resistance, long-term prophylactic antibiotics are not recommended.
[Guideline] World Health Organization. WHO Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulfur dioxide. Available at http://whqlibdoc.who.int/hq/2006/WHO_SDE_PHE_OEH_06.02_eng.pdf. Accessed: November 12, 2013.
Andersen ZJ, Kristiansen LC, Andersen KK, et al. Stroke and long-term exposure to outdoor air pollution from nitrogen dioxide: a cohort study. Stroke. 2012 Feb. 43(2):320-5. [Medline].
Chen R, Samoli E, Wong CM, Huang W, Wang Z, Chen B, et al. Associations between short-term exposure to nitrogen dioxide and mortality in 17 Chinese cities: the China Air Pollution and Health Effects Study (CAPES). Environ Int. 2012 Sep 15. 45:32-8. [Medline].
Environmental Protection Agency. Nitrogen Dioxide. Available at http://www.epa.gov/air/nitrogenoxides/health.html. Accessed: November 12, 2013.
Environmental Protection Agency. An Introduction to Indoor Air Quality (IAQ) - Nitrogen Dioxide (NO2). Available at http://www.epa.gov/iaq/no2.html. Accessed: November 12, 2013.
Stieb DM, Szyszkowicz M, Rowe BH, Leech JA. Air pollution and emergency department visits for cardiac and respiratory conditions: a multi-city time-series analysis. Environ Health. 2009 Jun 10. 8:25. [Medline]. [Full Text].
Environmental Protection Agency. National Ambient Air Quality Standards (NAAQS). Available at http://www.epa.gov/air/criteria.html. Accessed: November 12, 2013.
American Lung Association. Nitrogen Dioxide. Available at http://www.lung.org/healthy-air/outdoor/resources/nitrogen-dioxide.html. Accessed: November 12, 2013.
Environmental Protection Agency. National Trends in Nitrogen Dioxide Levels. Available at http://www.epa.gov/airtrends/nitrogen.html. Accessed: November 12, 2013.
Belanger K, Gent JF, Triche EW, Bracken MB, Leaderer BP. Association of indoor nitrogen dioxide exposure with respiratory symptoms in children with asthma. Am J Respir Crit Care Med. 2006 Feb 1. 173(3):297-303. [Medline]. [Full Text].
Lee K, Xue J, Geyh AS, Ozkaynak H, Leaderer BP, Weschler CJ, et al. Nitrous acid, nitrogen dioxide, and ozone concentrations in residential environments. Environ Health Perspect. 2002 Feb. 110(2):145-50. [Medline]. [Full Text].
van Strien RT, Gent JF, Belanger K, Triche E, Bracken MB, Leaderer BP. Exposure to NO2 and nitrous acid and respiratory symptoms in the first year of life. Epidemiology. 2004 Jul. 15(4):471-8. [Medline].
Kahan ES, Martin UJ, Spungen S, Ciccolella D, Criner GJ. Chronic cough and dyspnea in ice hockey players after an acute exposure to combustion products of a faulty ice resurfacer. Lung. 2007 Jan-Feb. 185(1):47-54. [Medline].
Centers for Disease Control and Prevention. Silo-Filler's disease in rural New York. MMWR Morb Mortal Wkly Rep. 1982 Jul 23. 31(28):389-91. [Medline].
Zwemer FL Jr, Pratt DS, May JJ. Silo filler's disease in New York State. Am Rev Respir Dis. 1992 Sep. 146(3):650-3. [Medline].
Hesterberg TW, Bunn WB, McClellan RO, Hamade AK, Long CM, Valberg PA. Critical review of the human data on short-term nitrogen dioxide (NO2) exposures: evidence for NO2 no-effect levels. Crit Rev Toxicol. 2009. 39(9):743-81. [Medline].
Kimbrough ES, Baldauf RW, Watkins N. Seasonal and diurnal analysis of NO2 concentrations from a long-duration study conducted in Las Vegas, Nevada. J Air Waste Manag Assoc. 2013 Aug. 63(8):934-42. [Medline].
Baldauf R, Thoma E, Hays M, et al. Traffic and meteorological impacts on near-road air quality: summary of methods and trends from the Raleigh Near-Road Study. J Air Waste Manag Assoc. 2008 Jul. 58(7):865-78. [Medline].
Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004 Jun 29. 109(25):3106-11. [Medline].
Romieu I, Sienra-Monge JJ, Ramírez-Aguilar M, Moreno-Macías H, Reyes-Ruiz NI, Estela del Río-Navarro B, et al. Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City. Thorax. 2004 Jan. 59(1):8-10. [Medline]. [Full Text].
Gilliland FD. Outdoor air pollution, genetic susceptibility, and asthma management: opportunities for intervention to reduce the burden of asthma. Pediatrics. 2009 Mar. 123 Suppl 3:S168-73. [Medline]. [Full Text].
Mushtaq N, Ezzati M, Hall L, et al. Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter. J Allergy Clin Immunol. 2011 May. 127(5):1236-42.e2. [Medline].
Neupane B, Jerrett M, Burnett RT, Marrie T, Arain A, Loeb M. Long-term exposure to ambient air pollution and risk of hospitalization with community-acquired pneumonia in older adults. Am J Respir Crit Care Med. 2010 Jan 1. 181(1):47-53. [Medline].
US Food and Drug Administration. FDA Drug Safety Communication: Serious CNS reactions possible when methylene blue is given to patients taking certain psychiatric medications. Available at http://www.fda.gov/Drugs/DrugSafety/ucm263190.htm. Accessed: July 27, 2011.